Laurie Glimcher, M.D, president and chief executive officer of Dana-Farber, is also chief executive officer of Dana-Farber/Partners CancerCare, director of Dana-Farber/Harvard Cancer Center, and a trustee of Dana-Farber/Children's Hospital Cancer Care. Glimcher helped develop Vice President Joe Biden's Moonshot initiative, and witnessed the 21st Century Cures Bill being signed into law.
Glimcher has served as the Stephen and Suzanne Weiss Dean and professor of medicine of Weill Cornell Medical College, and as Cornell's Provost for Medical Affairs. She has served as the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health, where she directed the Division of Biological Sciences. She was also professor of medicine at Harvard Medical School, where she headed one of the world's premier immunology programs.
Glimcher is a recipient of the many awards and honors and most recently received the prestigious AAMC (Association of American Medical Colleges) Award for Distinguished Research in the Biomedical Sciences. She has made numerous discoveries that have advanced treatments for many diseases and chronic conditions, including cancer, asthma, and osteoporosis. She is widely considered to be the international authority on the development and activation of lymphocytes in the immune system.
Glimcher is a Fellow of the American Academy of Arts and Sciences, a member of the National Academy of Medicine and a member of the National Academy of Sciences. She sits on the Board of Trustees of the Parker Institute for Cancer Immunotherapy and on the corporate board of directors of the Waters Corporation and GlaxoSmithKline plc.
A magna cum laude graduate of Radcliffe College with an MD degree cum laude from Harvard Medical School, Glimcher is the Richard and Susan Smith Professor of Medicine and a professor of Immunobiology at Harvard Medical School.